메뉴 건너뛰기




Volumn 27, Issue 11, 2013, Pages 971-988

Glatiramer acetate: A review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; N ACETYLASPARTIC ACID; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE;

EID: 84887109054     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0117-3     Document Type: Review
Times cited : (40)

References (99)
  • 1
    • 55549087746 scopus 로고    scopus 로고
    • World Health Organization Accessed 15 Jul 2013
    • World Health Organization. Atlas: multiple sclerosis resources in the world. 2008. http://www.who.int/mental-health/neurology/Atlas-MS-WEB.pdf. Accessed 15 Jul 2013.
    • (2008) Atlas: Multiple Sclerosis Resources in the World
  • 2
    • 84859724482 scopus 로고    scopus 로고
    • Multiple sclerosis
    • 22466660 10.1172/JCI58649 1:CAS:528:DC%2BC38Xlt1egtL8%3D
    • Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180-8.
    • (2012) J Clin Invest. , vol.122 , Issue.4 , pp. 1180-1188
    • Nylander, A.1    Hafler, D.A.2
  • 3
    • 0034727066 scopus 로고    scopus 로고
    • Multiple sclerosis
    • 11006371 10.1056/NEJM200009283431307 1:STN:280:DC%2BD3cvlvF2quw%3D%3D
    • Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343(13):938-52.
    • (2000) N Engl J Med. , vol.343 , Issue.13 , pp. 938-952
    • Noseworthy, J.H.1    Lucchinetti, C.2    Rodriguez, M.3
  • 4
    • 56549105235 scopus 로고    scopus 로고
    • Disease-modifying agents for multiple sclerosis: Recent advances and future prospects
    • 19016573 10.2165/0003495-200868170-00004 1:CAS:528:DC%2BD1MXitF2htbg%3D
    • Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008;68(17):2445-68.
    • (2008) Drugs. , vol.68 , Issue.17 , pp. 2445-2468
    • Menge, T.1    Weber, M.S.2    Hemmer, B.3
  • 5
    • 37249048528 scopus 로고    scopus 로고
    • Pharmacological treatment of early multiple sclerosis
    • 18081373 10.2165/00003495-200868010-00005 1:CAS:528:DC%2BD1cXisVOhurg%3D
    • Stuve O, Bennett JL, Hemmer B, et al. Pharmacological treatment of early multiple sclerosis. Drugs. 2008;68(1):73-83.
    • (2008) Drugs. , vol.68 , Issue.1 , pp. 73-83
    • Stuve, O.1    Bennett, J.L.2    Hemmer, B.3
  • 6
    • 77449096472 scopus 로고    scopus 로고
    • Current and future directions of MS management: Key considerations for managed care pharmacists
    • Lipsy RJ, Schapiro RT, Prostko CR. Current and future directions of MS management: key considerations for managed care pharmacists. J Manag Care Pharm. 2009;15(9 Suppl a):S2-15.
    • (2009) J Manag Care Pharm , vol.15 , Issue.9 SUPPL. A
    • Lipsy, R.J.1    Schapiro, R.T.2    Prostko, C.R.3
  • 7
    • 79551666754 scopus 로고    scopus 로고
    • Risks vs benefits of glatiramer acetate: A changing perspective as new therapies emerge for multiple sclerosis
    • 20421914 10.2147/TCRM.S6743 1:CAS:528:DC%2BC3cXltFyhsbs%3D
    • Johnson KP. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag. 2010;6:153-72.
    • (2010) Ther Clin Risk Manag. , vol.6 , pp. 153-172
    • Johnson, K.P.1
  • 8
    • 79953890862 scopus 로고    scopus 로고
    • Glatiramer acetate in the treatment of multiple sclerosis: Emerging concepts regarding its mechanism of action
    • 21476611 10.2165/11588120-000000000-00000 1:CAS:528:DC%2BC3MXot1yisL8%3D
    • Lalive PH, Neuhaus O, Benkhoucha M, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011;25(5):401-14.
    • (2011) CNS Drugs. , vol.25 , Issue.5 , pp. 401-414
    • Lalive, P.H.1    Neuhaus, O.2    Benkhoucha, M.3
  • 9
    • 77955442859 scopus 로고    scopus 로고
    • Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis
    • 20687620 10.2165/11204560-000000000-00000 1:CAS:528:DC%2BC3cXhtF2ks7vL
    • Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs. 2010;70(12):1545-77.
    • (2010) Drugs. , vol.70 , Issue.12 , pp. 1545-1577
    • Carter, N.J.1    Keating, G.M.2
  • 10
    • 84875232446 scopus 로고    scopus 로고
    • The mechanism of action of glatiramer acetate in multiple sclerosis and beyond
    • 23051633 10.1016/j.autrev.2012.09.005 1:CAS:528:DC%2BC38XhsF2hsbjI
    • Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev. 2013;12(5):543-53.
    • (2013) Autoimmun Rev. , vol.12 , Issue.5 , pp. 543-553
    • Aharoni, R.1
  • 11
    • 84870723327 scopus 로고    scopus 로고
    • Glatiramer acetate in treatment of multiple sclerosis: A toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?
    • 23203082 10.3390/ijms131114579 1:CAS:528:DC%2BC38XhvVaqurvM
    • Jalilian B, Einarsson HB, Vorup-Jensen T. Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system? Int J Mol Sci. 2012;13(11):14579-605.
    • (2012) Int J Mol Sci. , vol.13 , Issue.11 , pp. 14579-14605
    • Jalilian, B.1    Einarsson, H.B.2    Vorup-Jensen, T.3
  • 12
    • 40349089507 scopus 로고    scopus 로고
    • Glatiramer acetate: Evidence for a dual mechanism of action
    • 18317674 10.1007/s00415-008-1005-5 1:CAS:528:DC%2BD1cXovV2rur8%3D
    • Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol. 2008;255(Suppl 1):26-36.
    • (2008) J Neurol. , vol.255 , Issue.SUPPL. 1 , pp. 26-36
    • Blanchette, F.1    Neuhaus, O.2
  • 13
    • 0036450608 scopus 로고    scopus 로고
    • Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis
    • 12421116 10.2165/00023210-200216120-00004 1:CAS:528:DC%2BD38Xps1yjurw%3D
    • Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs. 2002;16(12):825-50.
    • (2002) CNS Drugs. , vol.16 , Issue.12 , pp. 825-850
    • Simpson, D.1    Noble, S.2    Perry, C.3
  • 14
    • 38449106357 scopus 로고    scopus 로고
    • Neurogenesis and neuroprotection in the CNS: Fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disorders
    • 17955199 10.1007/s12035-007-8002-z 1:CAS:528:DC%2BD2sXhtlWitrrE
    • Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS: fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol. 2007;36(3):245-53.
    • (2007) Mol Neurobiol. , vol.36 , Issue.3 , pp. 245-253
    • Arnon, R.1    Aharoni, R.2
  • 15
    • 79952101943 scopus 로고    scopus 로고
    • Patterns of Th1/Th2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate
    • 21372576 10.1159/000324035 1:CAS:528:DC%2BC3MXjslKrs7o%3D
    • Tumani H, Kassubek J, Hijazi M, et al. Patterns of Th1/Th2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. Eur Neurol. 2011;65(3):164-9.
    • (2011) Eur Neurol. , vol.65 , Issue.3 , pp. 164-169
    • Tumani, H.1    Kassubek, J.2    Hijazi, M.3
  • 16
    • 84866306371 scopus 로고    scopus 로고
    • TH1/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate or natalizumab
    • 22989378 10.1186/1471-2377-12-95 1:CAS:528:DC%2BC3sXit1CisLs%3D
    • Oreja-Guevara C, Ramos-Cejudo J, Aroeira LS, et al. TH1/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate or natalizumab. BMC Neurol. 2012;12:95.
    • (2012) BMC Neurol. , vol.12 , pp. 95
    • Oreja-Guevara, C.1    Ramos-Cejudo, J.2    Aroeira, L.S.3
  • 17
    • 0034691165 scopus 로고    scopus 로고
    • Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
    • 10861011 10.1073/pnas.97.13.7452 1:CAS:528:DC%2BD3cXksVKhsrk%3D
    • Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA. 2000;97(13):7452-7.
    • (2000) Proc Natl Acad Sci USA , vol.97 , Issue.13 , pp. 7452-7457
    • Neuhaus, O.1    Farina, C.2    Yassouridis, A.3
  • 18
    • 0034882744 scopus 로고    scopus 로고
    • Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS
    • 11548979 1:CAS:528:DC%2BD3MXmvVemtbc%3D
    • Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler. 2001;7(4):209-19.
    • (2001) Mult Scler. , vol.7 , Issue.4 , pp. 209-219
    • Chen, M.1    Gran, B.2    Costello, K.3
  • 19
    • 0037105959 scopus 로고    scopus 로고
    • Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years
    • 12163197 10.1016/S0022-510X(02)00201-0 1:CAS:528:DC%2BD38XmtVWmsbc%3D
    • Chen M, Conway K, Johnson KP, et al. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci. 2002;201(1-2):71-7.
    • (2002) J Neurol Sci. , vol.201 , Issue.1-2 , pp. 71-77
    • Chen, M.1    Conway, K.2    Johnson, K.P.3
  • 20
    • 0034041863 scopus 로고    scopus 로고
    • ®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
    • 10749576 10.1172/JCI8970 1:CAS:528:DC%2BD3cXit1yns70%3D
    • ®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000;105(7):967-76.
    • (2000) J Clin Invest. , vol.105 , Issue.7 , pp. 967-976
    • Duda, P.W.1    Schmied, M.C.2    Cook, S.L.3
  • 21
    • 0032427976 scopus 로고    scopus 로고
    • ®): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation
    • 9916886 10.1016/S0165-5728(98)00191-X 1:CAS:528:DyaK1cXnvVWis7o%3D
    • ®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol. 1998;92(1-2):113-21.
    • (1998) J Neuroimmunol. , vol.92 , Issue.1-2 , pp. 113-121
    • Miller, A.1    Shapiro, S.2    Gershtein, R.3
  • 22
    • 2442698974 scopus 로고    scopus 로고
    • Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis
    • 15153538 1:CAS:528:DC%2BD2cXktFSku7s%3D
    • Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004;172(11):7144-53.
    • (2004) J Immunol. , vol.172 , Issue.11 , pp. 7144-7153
    • Kim, H.J.1    Ifergan, I.2    Antel, J.P.3
  • 23
    • 33644861046 scopus 로고    scopus 로고
    • Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis
    • 10.1111/j.1365-2249.2006.02997.x 1:CAS:528:DC%2BD28Xit1alsrs%3D
    • Sanna A, Fois ML, Arru G, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exper Immunol. 2006;143(2):357-62.
    • (2006) Clin Exper Immunol. , vol.143 , Issue.2 , pp. 357-362
    • Sanna, A.1    Fois, M.L.2    Arru, G.3
  • 24
    • 84867029774 scopus 로고    scopus 로고
    • Classification of individuals based on ex-vivo glatiramer acetate-induced interferon- and interleukin-4 response
    • 22562951 10.1177/1352458512440349
    • Gilli F, Navone ND, Valentino P, et al. Classification of individuals based on ex-vivo glatiramer acetate-induced interferon- and interleukin-4 response. Mult Scler. 2012;18(10):1484-92.
    • (2012) Mult Scler. , vol.18 , Issue.10 , pp. 1484-1492
    • Gilli, F.1    Navone, N.D.2    Valentino, P.3
  • 25
    • 34447536807 scopus 로고    scopus 로고
    • Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis
    • 17613604 10.1177/1352458506074510 1:CAS:528:DC%2BD2sXpt1egt74%3D
    • Valenzuela RM, Costello K, Chen M, et al. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler. 2007;13(6):754-62.
    • (2007) Mult Scler. , vol.13 , Issue.6 , pp. 754-762
    • Valenzuela, R.M.1    Costello, K.2    Chen, M.3
  • 26
    • 76449085393 scopus 로고    scopus 로고
    • Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate
    • 20007428 10.1177/1352458509355460 1:CAS:528:DC%2BC3cXjvFGjsr8%3D
    • Chiarini M, Sottini A, Ghidini C, et al. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate. Mult Scler. 2010;16(2):218-27.
    • (2010) Mult Scler. , vol.16 , Issue.2 , pp. 218-227
    • Chiarini, M.1    Sottini, A.2    Ghidini, C.3
  • 27
    • 84862764134 scopus 로고    scopus 로고
    • Decreased microglial activation in MS patients treated with glatiramer acetate
    • 22160466 10.1007/s00415-011-6337-x 1:CAS:528:DC%2BC38XotF2msrY%3D
    • Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259(6):1199-205.
    • (2012) J Neurol. , vol.259 , Issue.6 , pp. 1199-1205
    • Ratchford, J.N.1    Endres, C.J.2    Hammoud, D.A.3
  • 28
    • 84872174912 scopus 로고    scopus 로고
    • Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis
    • 22653658 10.1177/1352458512450353 1:STN:280:DC%2BC38nnvFKjsA%3D%3D
    • Sellebjerg F, Hesse D, Limborg S, et al. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Mult Scler. 2013;19(2):179-87.
    • (2013) Mult Scler. , vol.19 , Issue.2 , pp. 179-187
    • Sellebjerg, F.1    Hesse, D.2    Limborg, S.3
  • 29
    • 84871429821 scopus 로고    scopus 로고
    • Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients
    • 23284793 10.1371/journal.pone.0051867 1:CAS:528:DC%2BC3sXlsVCltg%3D%3D
    • Pul R, Morbiducci F, Skuljec J, et al. Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients. PLoS ONE. 2012;7(12):e51867.
    • (2012) PLoS ONE. , vol.7 , Issue.12 , pp. 51867
    • Pul, R.1    Morbiducci, F.2    Skuljec, J.3
  • 30
    • 63149114677 scopus 로고    scopus 로고
    • Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis
    • 19255448 10.1073/pnas.0812183106 1:CAS:528:DC%2BD1MXjslCgs78%3D
    • Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA. 2009;106(11):4355-9.
    • (2009) Proc Natl Acad Sci USA , vol.106 , Issue.11 , pp. 4355-4359
    • Burger, D.1    Molnarfi, N.2    Weber, M.S.3
  • 31
    • 33646233989 scopus 로고    scopus 로고
    • Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis
    • 16513684 10.1093/brain/awl043
    • Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain. 2006;129(Pt 5):1293-305.
    • (2006) Brain. , vol.129 , Issue.PART 5 , pp. 1293-1305
    • Stasiolek, M.1    Bayas, A.2    Kruse, N.3
  • 32
    • 84876441375 scopus 로고    scopus 로고
    • A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA)
    • 23614042 10.1371/journal.pone.0062237
    • Hoglund RA, Holmoy T, Harbo HF, et al. A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA). PLoS ONE. 2013;8(4):e62237.
    • (2013) PLoS ONE. , vol.8 , Issue.4 , pp. 62237
    • Hoglund, R.A.1    Holmoy, T.2    Harbo, H.F.3
  • 33
    • 48349114325 scopus 로고    scopus 로고
    • Multiple sclerosis: Glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid
    • 18611988 10.1177/1352458508089411 1:CAS:528:DC%2BD1cXhtVWmtrfJ
    • Hestvik AL, Skorstad G, Price DA, et al. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler. 2008;14(6):749-58.
    • (2008) Mult Scler. , vol.14 , Issue.6 , pp. 749-758
    • Hestvik, A.L.1    Skorstad, G.2    Price, D.A.3
  • 35
    • 84857857741 scopus 로고    scopus 로고
    • Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis
    • 22020419 10.1177/1352458511420268 1:CAS:528:DC%2BC38Xmt1Cit7g%3D
    • Sellebjerg F, Hedegaard CJ, Krakauer M, et al. Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. Mult Scler. 2012;18(3):305-13.
    • (2012) Mult Scler. , vol.18 , Issue.3 , pp. 305-313
    • Sellebjerg, F.1    Hedegaard, C.J.2    Krakauer, M.3
  • 36
    • 0344098868 scopus 로고    scopus 로고
    • Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy
    • 14664472 10.1191/1352458503ms963oa 1:CAS:528:DC%2BD3sXhtVSqtr3L
    • Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler. 2003;9(6):592-9.
    • (2003) Mult Scler. , vol.9 , Issue.6 , pp. 592-599
    • Teitelbaum, D.1    Brenner, T.2    Abramsky, O.3
  • 37
    • 0035091667 scopus 로고    scopus 로고
    • European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group
    • 11261502 10.1002/ana.64 1:CAS:528:DC%2BD3MXisVyqtL0%3D
    • Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49(3):290-7.
    • (2001) Ann Neurol. , vol.49 , Issue.3 , pp. 290-297
    • Comi, G.1    Filippi, M.2    Wolinsky, J.S.3
  • 38
    • 0035964157 scopus 로고    scopus 로고
    • Glatiramer acetate reduces the proportion of new MS lesions evolving into black holes
    • 11524494 10.1212/WNL.57.4.731 1:CAS:528:DC%2BD3MXmslymt7g%3D
    • Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into black holes. Neurology. 2001;57(4):731-3.
    • (2001) Neurology. , vol.57 , Issue.4 , pp. 731-733
    • Filippi, M.1    Rovaris, M.2    Rocca, M.A.3
  • 39
    • 70350786389 scopus 로고    scopus 로고
    • Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial
    • 19815268 10.1016/S0140-6736(09)61259-9 1:CAS:528:DC%2BD1MXhtlCmt7zN
    • Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503-11.
    • (2009) Lancet. , vol.374 , Issue.9700 , pp. 1503-1511
    • Comi, G.1    Martinelli, V.2    Rodegher, M.3
  • 40
    • 56349112817 scopus 로고    scopus 로고
    • Glatirmaer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS
    • 18854910 10.1007/s00415-008-0911-x 1:CAS:528:DC%2BD1cXhsVGgurrN
    • Arnold DL, Campagnolo D, Panitch H, et al. Glatirmaer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol. 2008;255:1473-8.
    • (2008) J Neurol. , vol.255 , pp. 1473-1478
    • Arnold, D.L.1    Campagnolo, D.2    Panitch, H.3
  • 41
    • 80052853319 scopus 로고    scopus 로고
    • Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis
    • 21949733 10.1371/journal.pone.0024604 1:CAS:528:DC%2BC3MXht1yqsrbM
    • Waschbisch A, Atiya M, Linker RA, et al. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS ONE. 2011;6(9):e24604.
    • (2011) PLoS ONE. , vol.6 , Issue.9 , pp. 24604
    • Waschbisch, A.1    Atiya, M.2    Linker, R.A.3
  • 42
    • 74049156448 scopus 로고    scopus 로고
    • Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis
    • 19893201 10.1155/2009/267581 1:CAS:528:DC%2BD1MXhsFCitbvF
    • Achiron A, Feldman A, Gurevich M. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. Dis Markers. 2009;27(2):63-73.
    • (2009) Dis Markers. , vol.27 , Issue.2 , pp. 63-73
    • Achiron, A.1    Feldman, A.2    Gurevich, M.3
  • 43
    • 84875189394 scopus 로고    scopus 로고
    • Gene expression analysis reveals functional pathways of glatiramer acetate activation
    • 23469939 10.1517/14728222.2013.778829 1:CAS:528:DC%2BC3sXktFSkt7s%3D
    • Bakshi S, Chalifa-Caspi V, Plaschkes I, et al. Gene expression analysis reveals functional pathways of glatiramer acetate activation. Expert Opin Ther Targets. 2013;17(4):351-62.
    • (2013) Expert Opin Ther Targets. , vol.17 , Issue.4 , pp. 351-362
    • Bakshi, S.1    Chalifa-Caspi, V.2    Plaschkes, I.3
  • 45
    • 0029082566 scopus 로고
    • Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group
    • 7617181 10.1212/WNL.45.7.1268 1:STN:280:DyaK2Mzkt1eqtQ%3D%3D
    • Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.
    • (1995) Neurology. , vol.45 , Issue.7 , pp. 1268-1276
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3
  • 46
    • 51449101000 scopus 로고    scopus 로고
    • Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial
    • 18789766 10.1016/S1474-4422(08)70200-X 1:CAS:528:DC%2BD1cXht1enu7%2FN
    • Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903-14.
    • (2008) Lancet Neurol. , vol.7 , Issue.10 , pp. 903-914
    • Mikol, D.D.1    Barkhof, F.2    Chang, P.3
  • 47
    • 69949098534 scopus 로고    scopus 로고
    • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study
    • 19729344 10.1016/S1474-4422(09)70226-1
    • O'Connor P, Filippi M, Arnason B, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-97.
    • (2009) Lancet Neurol. , vol.8 , Issue.10 , pp. 889-897
    • O'Connor, P.1    Filippi, M.2    Arnason, B.3
  • 48
    • 67649476210 scopus 로고    scopus 로고
    • Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study
    • 19279320 10.1212/01.wnl.0000345970.73354.17 1:CAS:528: DC%2BD1MXms1yjtrs%3D
    • Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72:1976-83.
    • (2009) Neurology. , vol.72 , pp. 1976-1983
    • Cadavid, D.1    Wolansky, L.J.2    Skurnick, J.3
  • 49
    • 10744230723 scopus 로고    scopus 로고
    • Glatiramer acetate (Copaxone): Comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial
    • 14664471 10.1191/1352458503ms961oa 1:CAS:528:DC%2BD3sXhtVSqtr3I
    • Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler. 2003;9(6):585-91.
    • (2003) Mult Scler. , vol.9 , Issue.6 , pp. 585-591
    • Johnson, K.P.1    Brooks, B.R.2    Ford, C.C.3
  • 50
    • 6844254570 scopus 로고    scopus 로고
    • Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group
    • 9521260 10.1212/WNL.50.3.701 1:CAS:528:DyaK1cXitlymsLs%3D
    • Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50(3):701-8.
    • (1998) Neurology. , vol.50 , Issue.3 , pp. 701-708
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3
  • 51
    • 17744367204 scopus 로고    scopus 로고
    • United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
    • 11321192 1:CAS:528:DC%2BD3MXjs1eis74%3D
    • Wolinsky JS, Narayana PA, Johnson KP, et al. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler. 2001;7:33-41.
    • (2001) Mult Scler. , vol.7 , pp. 33-41
    • Wolinsky, J.S.1    Narayana, P.A.2    Johnson, K.P.3
  • 52
    • 12744273688 scopus 로고    scopus 로고
    • Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data
    • 15595937 10.1111/j.1600-0404.2004.00351.x 1:STN:280: DC%2BD2cnitVKksQ%3D%3D
    • Johnson KP, Ford CC, Lisak RP, et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand. 2005;111(1):42-7.
    • (2005) Acta Neurol Scand. , vol.111 , Issue.1 , pp. 42-47
    • Johnson, K.P.1    Ford, C.C.2    Lisak, R.P.3
  • 53
    • 33744814611 scopus 로고    scopus 로고
    • A prospective open-label study of glatiramer acetate: Over a decade of continuous use in multiple sclerosis patients
    • 16764344 10.1191/135248506ms1318oa 1:STN:280:DC%2BD28zltVKmtQ%3D%3D
    • Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler. 2006;12(3):309-20.
    • (2006) Mult Scler. , vol.12 , Issue.3 , pp. 309-320
    • Ford, C.C.1    Johnson, K.P.2    Lisak, R.P.3
  • 54
    • 77949885488 scopus 로고    scopus 로고
    • Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
    • 20106943 10.1177/1352458509358088 1:CAS:528:DC%2BC3cXlt1Olt7w%3D
    • Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010;16(3):342-50.
    • (2010) Mult Scler. , vol.16 , Issue.3 , pp. 342-350
    • Ford, C.1    Goodman, A.D.2    Johnson, K.3
  • 55
    • 18344409394 scopus 로고    scopus 로고
    • Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment
    • 10690968 10.1212/WNL.54.4.813 1:CAS:528:DC%2BD3cXhs1Gqsrs%3D
    • Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology. 2000;54(4):813-7.
    • (2000) Neurology. , vol.54 , Issue.4 , pp. 813-817
    • Ge, Y.1    Grossman, R.I.2    Udupa, J.K.3
  • 56
    • 33947106112 scopus 로고    scopus 로고
    • Cognitive function in relapsing multiple sclerosis: Minimal changes in a 10-year clinical trial
    • 17331542 10.1016/j.jns.2007.01.070
    • Schwid SR, Goodman AD, Weinstein A, et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci. 2007;255(1-2):57-63.
    • (2007) J Neurol Sci. , vol.255 , Issue.1-2 , pp. 57-63
    • Schwid, S.R.1    Goodman, A.D.2    Weinstein, A.3
  • 57
    • 0037159225 scopus 로고    scopus 로고
    • Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained
    • 12391370 10.1212/WNL.59.8.1284 1:CAS:528:DC%2BD38Xns1Sns78%3D
    • Wolinsky JS, Comi G, Filippi M, et al. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology. 2002;59(8):1284-6.
    • (2002) Neurology. , vol.59 , Issue.8 , pp. 1284-1286
    • Wolinsky, J.S.1    Comi, G.2    Filippi, M.3
  • 58
    • 85081795751 scopus 로고    scopus 로고
    • Efficacy of glatiramer acetate in Czech multicentre observational study in the period 2006-2010 [abstract no. P1041]
    • Stourac P, Praksova P, Kontrova I, et al. Efficacy of glatiramer acetate in Czech multicentre observational study in the period 2006-2010 [abstract no. P1041]. Mult Scler. 2011;17(Suppl):S475.
    • (2011) Mult Scler. , vol.17 , Issue.SUPPL. , pp. 475
    • Stourac, P.1    Praksova, P.2    Kontrova, I.3
  • 59
    • 77956662173 scopus 로고    scopus 로고
    • Glatiramer acetate and interferon beta-1a for intramuscular administration: A study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts
    • 20662760 10.3111/13696998.2010.496650
    • Castelli-Haley J, Oleen-Burkey MA, Lage MJ, et al. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ. 2010;13(3):464-71.
    • (2010) J Med Econ. , vol.13 , Issue.3 , pp. 464-471
    • Castelli-Haley, J.1    Oleen-Burkey, M.A.2    Lage, M.J.3
  • 60
    • 84866355653 scopus 로고    scopus 로고
    • Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis [Erratum appears in N Engl J Med. 2012 Oct 25;367(17):1673]
    • 22992072 10.1056/NEJMoa1206328 1:CAS:528:DC%2BC38XhsVKkur3E
    • Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis [Erratum appears in N Engl J Med. 2012 Oct 25;367(17):1673]. N Engl J Med. 2012;367(12):1087-97.
    • (2012) N Engl J Med. , vol.367 , Issue.12 , pp. 1087-1097
    • Fox, R.J.1    Miller, D.H.2    Phillips, J.T.3
  • 61
    • 52449091605 scopus 로고    scopus 로고
    • Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
    • 18775064 10.1186/1477-7525-6-67
    • Ziemssen T, Hoffman J, Apfel R, et al. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes. 2008;6:67.
    • (2008) Health Qual Life Outcomes. , vol.6 , pp. 67
    • Ziemssen, T.1    Hoffman, J.2    Apfel, R.3
  • 62
    • 78149450871 scopus 로고    scopus 로고
    • Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: A prospective, observational, international, multi-centre study
    • 21078142 10.1186/1477-7525-8-133
    • Jongen PJ, Lehnick D, Sanders E, et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes. 2010;8:133.
    • (2010) Health Qual Life Outcomes. , vol.8 , pp. 133
    • Jongen, P.J.1    Lehnick, D.2    Sanders, E.3
  • 63
    • 85081794974 scopus 로고    scopus 로고
    • Insights from the Coptimize study: Characteristics of relapsing-remitting multiple sclerosis patients switching to glatiramer acetate [abstract no. P510]
    • Ziemssen T, Carra A, De Klippel N, et al. Insights from the Coptimize study: characteristics of relapsing-remitting multiple sclerosis patients switching to glatiramer acetate [abstract no. P510]. Mult Scler. 2011;17:S218.
    • (2011) Mult Scler. , vol.17 , pp. 218
    • Ziemssen, T.1    Carra, A.2    De Klippel, N.3
  • 64
    • 33745923816 scopus 로고    scopus 로고
    • Glatiramer acetate in treatment-naive and prior interferon-β-1b- treated multiple sclerosis patients
    • 16674604 10.1111/j.1600-0404.2006.00627.x 1:STN:280: DC%2BD28zhsVCkuw%3D%3D
    • Zwibel HL. Glatiramer acetate in treatment-naive and prior interferon-β-1b-treated multiple sclerosis patients. Acta Neurol Scand. 2006;113(6):378-86.
    • (2006) Acta Neurol Scand. , vol.113 , Issue.6 , pp. 378-386
    • Zwibel, H.L.1
  • 65
    • 77954625890 scopus 로고    scopus 로고
    • Effects of glatiramer acetate on spasticity in previously interferon-β-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: A prospective, nonrandomized, open-label, uncontrolled, observational pilot study
    • 20637960 10.1016/j.clinthera.2010.06.005 1:CAS:528:DC%2BC3cXpsVGhs74%3D
    • Meca-Lallana JE, de Mingo-Casado P, Amorin-Diaz M, et al. Effects of glatiramer acetate on spasticity in previously interferon-β-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Clin Ther. 2010;32(6):1061-6.
    • (2010) Clin Ther. , vol.32 , Issue.6 , pp. 1061-1066
    • Meca-Lallana, J.E.1    De Mingo-Casado, P.2    Amorin-Diaz, M.3
  • 66
    • 84871652136 scopus 로고    scopus 로고
    • Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab
    • 22741530 10.1111/j.1468-1331.2012.03794.x 1:STN:280: DC%2BC38jls1Siuw%3D%3D
    • Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol. 2013;20(1):87-94.
    • (2013) Eur J Neurol. , vol.20 , Issue.1 , pp. 87-94
    • Rossi, S.1    Motta, C.2    Studer, V.3
  • 67
    • 0034853968 scopus 로고    scopus 로고
    • Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications
    • 11522582 10.1093/brain/124.9.1803 1:STN:280:DC%2BD3MvnvVymtQ%3D%3D
    • Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain. 2001;124(9):1803-12.
    • (2001) Brain. , vol.124 , Issue.9 , pp. 1803-1812
    • Rovaris, M.1    Comi, G.2    Rocca, M.A.3
  • 68
    • 79954574768 scopus 로고    scopus 로고
    • Interferon β-1b and glatiramer acetate effects on permanent black hole evolution
    • 21464426 10.1212/WNL.0b013e3182143577 1:CAS:528:DC%2BC3MXkt1Kmsbs%3D
    • Filippi M, Rocca MA, Camesasca F, et al. Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011;76(14):1222-8.
    • (2011) Neurology. , vol.76 , Issue.14 , pp. 1222-1228
    • Filippi, M.1    Rocca, M.A.2    Camesasca, F.3
  • 69
    • 70449360324 scopus 로고    scopus 로고
    • New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate
    • 19687024 10.1136/jnnp.2008.171090 1:STN:280:DC%2BD1Mjmt1Shtg%3D%3D
    • Cadavid D, Cheriyan J, Skurnick J, et al. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry. 2009;80(12):1337-43.
    • (2009) J Neurol Neurosurg Psychiatry. , vol.80 , Issue.12 , pp. 1337-1343
    • Cadavid, D.1    Cheriyan, J.2    Skurnick, J.3
  • 70
    • 46849091551 scopus 로고    scopus 로고
    • Galtiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis
    • 18424479 10.1177/1352458507085759 1:CAS:528:DC%2BD1cXovFCjtrk%3D
    • Vollmer T, Panitch H, Bar-Or A, et al. Galtiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008;14(5):663-70.
    • (2008) Mult Scler. , vol.14 , Issue.5 , pp. 663-670
    • Vollmer, T.1    Panitch, H.2    Bar-Or, A.3
  • 71
    • 84857714278 scopus 로고    scopus 로고
    • The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics
    • 22754793 10.1016/j.msard.2012.01.006 1:CAS:528:DC%2BC38XptF2rt7s%3D
    • Lindsey JW, Scott TF, Lynch SG, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Mult Scler Relat Disord. 2012;1(2):81-6.
    • (2012) Mult Scler Relat Disord. , vol.1 , Issue.2 , pp. 81-86
    • Lindsey, J.W.1    Scott, T.F.2    Lynch, S.G.3
  • 72
    • 84876473109 scopus 로고    scopus 로고
    • Randomized study combining interferon and glatiramer acetate in multiple sclerosis
    • 23424159 10.1002/ana.23863 1:CAS:528:DC%2BC3sXmt1OjurY%3D
    • Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73:327-40.
    • (2013) Ann Neurol. , vol.73 , pp. 327-340
    • Lublin, F.D.1    Cofield, S.S.2    Cutter, G.R.3
  • 73
    • 62849118791 scopus 로고    scopus 로고
    • GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study
    • 19255407 10.1212/01.wnl.0000343880.13764.69 1:CAS:528: DC%2BD1MXit1Cgurw%3D
    • Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806-12.
    • (2009) Neurology. , vol.72 , Issue.9 , pp. 806-812
    • Goodman, A.D.1    Rossman, H.2    Bar-Or, A.3
  • 74
    • 84879752237 scopus 로고    scopus 로고
    • Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome
    • 23234810 10.1177/1352458512469695
    • Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013;19(8):1074-83.
    • (2013) Mult Scler. , vol.19 , Issue.8 , pp. 1074-1083
    • Comi, G.1    Martinelli, V.2    Rodegher, M.3
  • 75
    • 84880276763 scopus 로고    scopus 로고
    • Neuroprotection with glatiramer acetate: Evidence from the PreCISe trial
    • 23589190 10.1007/s00415-013-6903-5 1:CAS:528:DC%2BC3sXhtV2ktLjM
    • Arnold DL, Narayana S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol. 2013;260:1901-6.
    • (2013) J Neurol. , vol.260 , pp. 1901-1906
    • Arnold, D.L.1    Narayana, S.2    Antel, S.3
  • 76
    • 78651262547 scopus 로고    scopus 로고
    • Glatiramer acetate exposure in pregnancy: Preliminary safety and birth outcomes
    • 20625758 10.1007/s00415-010-5652-y 1:CAS:528:DC%2BC3cXhsVymsrvM
    • Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 2010;257(12):2020-3.
    • (2010) J Neurol. , vol.257 , Issue.12 , pp. 2020-2023
    • Salminen, H.J.1    Leggett, H.2    Boggild, M.3
  • 77
    • 84867657238 scopus 로고    scopus 로고
    • Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: A prospective observational multicentric study
    • 23088447 10.1186/1471-2377-12-124 1:CAS:528:DC%2BC38XhslCisL%2FI
    • Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;12:124.
    • (2012) BMC Neurol. , vol.12 , pp. 124
    • Giannini, M.1    Portaccio, E.2    Ghezzi, A.3
  • 78
    • 77957850617 scopus 로고    scopus 로고
    • Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: A retrospective, multicentre case series
    • 20806993 1:CAS:528:DC%2BC3cXhsFygs73O
    • Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs. 2010;24(11):969-76.
    • (2010) CNS Drugs. , vol.24 , Issue.11 , pp. 969-976
    • Fragoso, Y.D.1    Finkelsztejn, A.2    Kaimen-Maciel, D.R.3
  • 81
    • 85081793503 scopus 로고    scopus 로고
    • National Institute for Clinical Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care (Clinical Guideline 8)
    • National Institute for Clinical Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care (Clinical Guideline 8). 2003. http://www.nice.org.uk/nicemedia/pdf/cg008guidance.pdf. Accessed 17 Jul 2013.
    • (2003)
  • 82
    • 85081795765 scopus 로고    scopus 로고
    • National Clinical Advisory Board of the National Multiple Sclerosis Society Accessed 16 Jul 2013
    • National Clinical Advisory Board of the National Multiple Sclerosis Society. Treatment recommendations for physicians: disease management consensus statement. 2007. http://www.nationalmssociety.org/about-multiple-sclerosis/ treatments/download.aspx?id=8. Accessed 16 Jul 2013.
    • (2007) Treatment Recommendations for Physicians: Disease Management Consensus Statement
  • 83
    • 84887044784 scopus 로고    scopus 로고
    • Association of British Neurologists. Association of British Neurologists: revised Accessed 16 Jul 2013
    • Association of British Neurologists. Association of British Neurologists: revised (2009) guidelines for prescribing in multiple sclerosis. 2009. http://www.theabn.org/abn/userfiles/file/abn-ms-guidelines-2009-final.pdf. Accessed 16 Jul 2013.
    • (2009) Guidelines for Prescribing in Multiple Sclerosis
  • 84
    • 0037154192 scopus 로고    scopus 로고
    • Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
    • 11805241 10.1212/WNL.58.2.169 1:STN:280:DC%2BD38%2FnvV2htw%3D%3D
    • Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-78.
    • (2002) Neurology. , vol.58 , Issue.2 , pp. 169-178
    • Goodin, D.S.1    Frohman, E.M.2    Garmany, G.P.3
  • 85
    • 79960855026 scopus 로고    scopus 로고
    • Fingolimod: A review of its use in the management of relapsing-remitting multiple sclerosis
    • 21790210 10.2165/11207350-000000000-00000 1:CAS:528:DC%2BC3MXht1eqsLfL
    • Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25(8):673-98.
    • (2011) CNS Drugs. , vol.25 , Issue.8 , pp. 673-698
    • Scott, L.J.1
  • 86
    • 79952016751 scopus 로고    scopus 로고
    • Future clinical challenges in multiple sclerosis: Relevance of sphingosine 1-phosphate receptor modulator therapy
    • 21339488 10.1212/WNL.0b013e31820db40f 1:CAS:528:DC%2BC3MXit1artbs%3D
    • Hohlfeld R, Barkhof F, Polman C. Future clinical challenges in multiple sclerosis: relevance of sphingosine 1-phosphate receptor modulator therapy. Neurology. 2011;76(8 Suppl 3):S28-37.
    • (2011) Neurology. , vol.76 , Issue.SUPPL. 3
    • Hohlfeld, R.1    Barkhof, F.2    Polman, C.3
  • 87
    • 79955432850 scopus 로고    scopus 로고
    • European Medicines Agency Accessed 22 Jul 2013
    • European Medicines Agency. Gilenya: summary of product characteristics 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002202/WC500104528.pdf. Accessed 22 Jul 2013.
    • Gilenya: Summary of Product Characteristics 2013
  • 88
    • 72049130492 scopus 로고    scopus 로고
    • Gilenya™: USA prescribing information Accessed 22 Jul 2013
    • Novartis Pharmaceuticals Corporation. Gilenya™: USA prescribing information. 2012. http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis. com/product/pi/pdf/gilenya.pdf. Accessed 22 Jul 2013.
    • (2012) Novartis Pharmaceuticals Corporation
  • 89
    • 84887059720 scopus 로고    scopus 로고
    • USA Food and Drug Administration Accessed 23 Jul 2013
    • USA Food and Drug Administration. FDA approves new multiple sclerosis treatment: Tecfidera. 2013. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm345528.htm. Accessed 23 Jul 2013.
    • (2013) FDA Approves New Multiple Sclerosis Treatment: Tecfidera
  • 90
    • 79251473278 scopus 로고    scopus 로고
    • European Medicines Agency Accessed 23 Jul 2013
    • European Medicines Agency. Summary of opinion (initial authorisation): tecfidera (dimethyl fumarate). 2013. http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/002601/smops/Positive/human-smop-000498. jsp&mid=WC0b01ac058001d127&source=homeMedSearch&category=human. Accessed 23 Jul 2013.
    • (2013) Summary of Opinion (Initial Authorisation): Tecfidera (Dimethyl Fumarate)
  • 92
    • 84887059720 scopus 로고    scopus 로고
    • USA Food and Drug Administration Accessed 23 Jul 2013
    • USA Food and Drug Administration. FDA approves new multiple sclerosis treatment: Aubagio (teriflunomide). 2013. http://www.ema.europa.eu/docs/en-GB/ document-library/Summary-of-opinion-Initial-authorisation/human/002514/ WC500144913.pdf. Accessed 23 Jul 2013.
    • (2013) FDA Approves New Multiple Sclerosis Treatment: Aubagio (Teriflunomide)
  • 93
    • 82455212856 scopus 로고    scopus 로고
    • Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: Retrospective claims analysis
    • 21870169 10.1007/s12325-011-0054-9 1:CAS:528:DC%2BC3MXhtFyjsrjI
    • Halpern R, Agarwal S, Borton L, et al. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther. 2011;28(9):761-75.
    • (2011) Adv Ther. , vol.28 , Issue.9 , pp. 761-775
    • Halpern, R.1    Agarwal, S.2    Borton, L.3
  • 94
    • 78650128757 scopus 로고    scopus 로고
    • The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    • 20561039 10.1111/j.1468-1331.2010.03110.x 1:STN:280: DC%2BC3M%2FntlWntQ%3D%3D
    • Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69-77.
    • (2011) Eur J Neurol. , vol.18 , Issue.1 , pp. 69-77
    • Devonshire, V.1    Lapierre, Y.2    Macdonell, R.3
  • 95
    • 58149352870 scopus 로고    scopus 로고
    • Early treatment of multiple sclerosis to prevent neurologic damage
    • 1:CAS:528:DC%2BD1cXhsVOgsLnM
    • Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurol. 2008;71(24 Suppl 3):S3-7.
    • (2008) Neurol. , vol.71 , Issue.SUPPL. 3
    • Coyle, P.K.1
  • 96
    • 84881226959 scopus 로고    scopus 로고
    • Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
    • 23686821 10.1002/ana.23938 1:CAS:528:DC%2BC3sXhtFCks73E
    • Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705-13.
    • (2013) Ann Neurol. , vol.73 , Issue.6 , pp. 705-713
    • Khan, O.1    Rieckmann, P.2    Boyko, A.3
  • 97
    • 77956089192 scopus 로고    scopus 로고
    • Pharmacoeconomic considerations in the treatment of multiple sclerosis
    • 20731475 10.2165/11538000-000000000-00000 1:CAS:528:DC%2BC3cXhtlaku77N
    • Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010;70(13):1677-91.
    • (2010) Drugs. , vol.70 , Issue.13 , pp. 1677-1691
    • Sharac, J.1    McCrone, P.2    Sabes-Figuera, R.3
  • 98
    • 34248380578 scopus 로고    scopus 로고
    • Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: A Markov model based on long-term clinical data
    • 17407391
    • Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245-61.
    • (2007) J Manag Care Pharm. , vol.13 , Issue.3 , pp. 245-261
    • Bell, C.1    Graham, J.2    Earnshaw, S.3
  • 99
    • 67650065019 scopus 로고    scopus 로고
    • Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population
    • 19508662 10.1111/j.1524-4733.2008.00485.x
    • Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health. 2009;12(5):657-65.
    • (2009) Value Health. , vol.12 , Issue.5 , pp. 657-665
    • Tappenden, P.1    McCabe, C.2    Chilcott, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.